• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Rifaximin-α in alcohol-associated liver disease.

作者信息

Xie Chencheng, Singal Ashwani K

机构信息

Department of Medicine, University of South Dakota Sanford School of Medicine, Sioux Falls, SD 57105, USA; Division of Transplant Hepatology, Avera Transplant Institute, Sioux Falls, SD, USA.

Department of Medicine, University of South Dakota Sanford School of Medicine, Sioux Falls, SD 57105, USA; Division of Transplant Hepatology, Avera Transplant Institute, Sioux Falls, SD, USA; Clinical Research, VA Medical Center, Sioux Falls, SD, USA.

出版信息

Lancet Gastroenterol Hepatol. 2023 Jun;8(6):495-497. doi: 10.1016/S2468-1253(23)00033-X. Epub 2023 Mar 6.

DOI:10.1016/S2468-1253(23)00033-X
PMID:36893773
Abstract
摘要

相似文献

1
Rifaximin-α in alcohol-associated liver disease.利福昔明-α在酒精性肝病中的应用
Lancet Gastroenterol Hepatol. 2023 Jun;8(6):495-497. doi: 10.1016/S2468-1253(23)00033-X. Epub 2023 Mar 6.
2
Changes in the Body Composition and Nutritional Status after Long-term Rifaximin Therapy for Hyperammonemia in Japanese Patients with Hepatic Encephalopathy.长期利福昔明治疗肝性脑病伴高血氨症日本患者的身体成分和营养状况变化。
Intern Med. 2020;59(20):2465-2469. doi: 10.2169/internalmedicine.5094-20. Epub 2020 Oct 15.
3
[Role of rifaximin in the treatment of hepatic encephalopathy].利福昔明在肝性脑病治疗中的作用
Gastroenterol Hepatol. 2016 Apr;39(4):282-92. doi: 10.1016/j.gastrohep.2015.08.003. Epub 2015 Nov 3.
4
Prognostic significance of hepatic encephalopathy in patients with cirrhosis treated with current standards of care.当前治疗标准下肝硬化患者肝性脑病的预后意义。
World J Gastroenterol. 2020 May 14;26(18):2221-2231. doi: 10.3748/wjg.v26.i18.2221.
5
Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy.肝硬化和肝性脑病患者的细菌宏基因组和病毒组的相互作用。
Gut. 2021 Jun;70(6):1162-1173. doi: 10.1136/gutjnl-2020-322470. Epub 2020 Sep 30.
6
Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis.综述文章：利福昔明治疗肝性脑病和肝硬化其他并发症的作用机制。
Aliment Pharmacol Ther. 2016 Jan;43 Suppl 1:11-26. doi: 10.1111/apt.13435.
7
Uncommon Movement Disorders in Chronic Hepatic Disease with Response to Rifaximin.慢性肝病中的罕见运动障碍及对利福昔明的反应
Tremor Other Hyperkinet Mov (N Y). 2019 Aug 2;9. doi: 10.7916/tohm.v0.649. eCollection 2019.
8
Racial and ethnic disparities in rifaximin use and subspecialty referrals for patients with hepatic encephalopathy in the United States.美国肝性脑病患者使用利福昔明和转至各亚专科的种族和民族差异。
J Hepatol. 2022 Aug;77(2):377-382. doi: 10.1016/j.jhep.2022.02.010. Epub 2022 Mar 30.
9
Effects of Alcohol on the Brain in Cirrhosis: Beyond Hepatic Encephalopathy.肝硬化患者大脑受酒精影响：不止肝性脑病。
Alcohol Clin Exp Res. 2018 Apr;42(4):660-667. doi: 10.1111/acer.13605. Epub 2018 Feb 27.
10
Comparative Efficacy of Treatment Options for the Prevention of Post-TIPS Hepatic Encephalopathy: A Systematic Review and Network Meta-analysis.经颈静脉肝内门体分流术（TIPS）后肝性脑病预防治疗方案的疗效比较：系统评价和网络荟萃分析。
J Gastrointestin Liver Dis. 2023 Apr 1;32(1):70-76. doi: 10.15403/jgld-4508.

引用本文的文献

1
Alcohol-related liver disease (ALD): current perspectives on pathogenesis, therapeutic strategies, and animal models.酒精性肝病（ALD）：关于发病机制、治疗策略及动物模型的当前观点
Front Pharmacol. 2024 Nov 28;15:1432480. doi: 10.3389/fphar.2024.1432480. eCollection 2024.
2
Rifaximin-α: A Promising Ally in the Battle Against Alcohol-Related Liver Disease.利福昔明-α：对抗酒精性肝病的有力新帮手
J Clin Exp Hepatol. 2024 Jan-Feb;14(1):101218. doi: 10.1016/j.jceh.2023.07.005. Epub 2023 Nov 22.
3
Rifaximin Alfa and Liver Diseases: More Than a Treatment for Encephalopathy, a Disease Modifier.
阿法环丙沙星与肝脏疾病：不仅仅是一种治疗肝性脑病的药物，更是一种疾病改善药物。
Ther Clin Risk Manag. 2023 Oct 24;19:839-851. doi: 10.2147/TCRM.S425292. eCollection 2023.